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Abstract
 
We have previously shown that antimicrobial peptides like defensins have the capacity to mo-
bilize leukocytes in host defense. LL-37 is the cleaved antimicrobial 37-residue, COOH-termi-
nal peptide of hCAP18 (human cationic antimicrobial protein with a molecular size of 18 kD),
the only identified member in humans of a family of proteins called cathelicidins. LL-37/
hCAP18 is produced by neutrophils and various epithelial cells. Here we report that LL-37 is
 
chemotactic for, and can induce Ca
 
2
 
1
 
 mobilization in, human monocytes and formyl peptide
receptor–like 1 (FPRL1)-transfected human embryonic kidney 293 cells. LL-37–induced Ca
 
2
 
1
 
mobilization in monocytes can also be cross-desensitized by an FPRL1-specific agonist. Fur-
thermore, LL-37 is also chemotactic for human neutrophils and T lymphocytes that are known
to express FPRL1. Our results suggest that, in addition to its microbicidal activity, LL-37 may
contribute to innate and adaptive immunity by recruiting neutrophils, monocytes, and T cells
to sites of microbial invasion by interacting with FPRL1.
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Introduction
 
A variety of small (
 
,
 
100 amino acids) antimicrobial pep-
tides, produced by cells of insects, plants, and animals, act as
endogenous antibiotics. In humans, over a dozen of these
antimicrobial peptides have thus far been identified and in-
clude several salivary histatins, lactoferricin, six 
 
a
 
-defensins,
two 
 
b
 
-defensins, and an 18-kD human cationic antimicro-
bial protein, hCAP18 (1). hCAP18, a protein possessing
140 amino acid residues (references 2–4), belongs to a fam-
ily of proteins called cathelicidins, which usually consist of
 
a highly conserved preproregion of 
 
z
 
128–143 residues, in-
cluding a putative 
 
z
 
29–30-residue signal peptide and a
 
z
 
99–114-residue cathelin-like domain and a COOH-ter-
minal antimicrobial domain ranging in length from 12 to
 
.
 
100 amino acid residues (5). The COOH-terminal do-
main of hCAP18 also has the capacity to bind and neutral-
ize bacterial LPS (2). Cleavage of hCAP18 was initially
predicted (2, 3) and later confirmed (6) to occur between
Ala103 and Leu104, giving rise to LL-37, a 37-residue ma-
ture antimicrobial peptide with two leucine residues on its
NH
 
2
 
 terminus. LL-37/hCAP18 is present in neutrophil
granules (3) and is produced by bone marrow and testis (4),
inflamed skin keratinocytes (7), lung epithelia (8), and
squamous epithelia of human mouth, tongue, esophagus,
cervix, and vagina (9). Both purified and chemically syn-
thesized LL-37 peptides exhibit potent and comparable an-
timicrobial activities in vitro (6, 10).
Although antimicrobial peptides have generally been
considered to contribute to host innate antimicrobial de-
fense (1), some of them may also contribute to adaptive
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immunity against microbial infection in higher vertebrates.
Human neutrophil 
 
a
 
-defensin is chemotactic for human
peripheral blood CD4/CD45RA and CD8 T cells, as well
as immature dendritic cells (11, 12). When administered si-
multaneously with protein antigens to mice, human 
 
a
 
-defen-
sins can promote antigen-specific immune responses (13).
Similarly, human epithelial cell derived 
 
b
 
-defensins have
the capacity to induce the migration of human peripheral
blood CD4/CD45RO T cells and immature dendritic cells
by interacting with one of the chemokine receptors,
CCR6 (14). However, it is not known whether antimicro-
bial peptides other than defensins (e.g., LL-37) have similar
activities.
In the course of characterizing neutrophil granule–derived
monocyte chemotactic activities, we previously established
that the major HPLC peak of activity was attributable to
cathepsin G (15). Another broader peak with significant
chemotactic activity contained a complex mixture of pro-
teins. By the use of more recently developed sensitive mass
spectroscopic methods, we have identified most of the
proteins present in that peak, one of them being LL-37
(Wooters, J., E. Nickbarg, and O. Chertov, unpublished
observation). PR-39, the COOH-terminal antimicrobial
peptide of one member of the porcine cathelicidins, has
been reported to have the capacity to chemoattract porcine
neutrophils (16). Therefore, we sought to determine whether
LL-37 could chemoattract human leukocytes. The results
indicate that LL-37 utilizes formyl peptide receptor–like 1
(FPRL1) as a receptor to activate human neutrophils,
monocytes, and T cells.
 
Materials and Methods
 
Media and Reagents.
 
DME and RPMI 1640 were purchased
from Biowhittaker. Synthetic fMLP (
 
N
 
-formyl-Met-Leu-Phe)
and human AB serum were purchased from Sigma-Aldrich. FBS
was purchased from Hyclone. Su peptide, a shorter version (lack-
ing the NH
 
2
 
-terminal five amino acids) of T21/DP107 corre-
sponding to amino acid 563–595 of HIV envelope protein gp41
(17), was synthesized and purified by Macromolecular Resources.
Su peptide is a specific agonist for FPRL1 receptor (Wang, J.M.,
unpublished observation). Su peptide was 99% pure as verified by
mass spectrometry. LL-37 was synthesized by solid phase Fmoc
(9-fluorenylmethyloxycarbonyl) chemistry. The first 11 amino
acids were each coupled once, and the remaining amino acids
were doubly coupled. After cleavage from the resin, the peptide
was dissolved in buffer A and purified by reverse phase chroma-
tography on a Dynamax C18 HPLC column using a gradient of
5–30% B in A buffer in 10 min, followed by 30–100% B in 90
min at a flow rate of 45 ml/min (buffer A: 0.1% TFA in water;
buffer B: 0.1% TFA in acetonitrile). The fractions were charac-
terized by analytical HPLC, mass spectrometry, and capillary
electrophoresis, combined, and lyophilized. The LL-37 peptide
thus prepared was 99.9% pure. Both LL-37 and Su peptide solu-
tions were free of endotoxin.
 
Cells.
 
Human PBMCs were isolated from leukopacks (cour-
tesy of the Transfusion Medicine Department, National Institutes
of Health [NIH] Clinic Center, Bethesda, MD) by routine Fi-
coll–Hypaque density gradient centrifugation. Monocytes were
purified from human PBMCs with the use of a MACS™ CD14
 
monocyte isolation kit (Miltenyi Biotec) according to the manu-
facturer’s recommendation (12). Neutrophils were purified from
the same leukopacks by 3% dextran sedimentation. T cells were
purified from PBMCs by the use of Human CD4 T Cell Enrich-
ment Columns (R&D Systems) (12). The purity of neutrophils,
monocytes, and T cells by FACScan™ (Becton Dickinson) anal-
ysis was 
 
.
 
95%. Rat basophilic leukemia cells stably transfected
with epitope-tagged FPR (ETFR cells) were provided by Drs.
H. Ali and R. Snyderman (Duke University, Durham, NC) and
maintained in the presence of 0.8 mg/ml of geneticin in DME
supplemented with 10% FBS. Human embryonic kidney
(HEK)293 cells stably transfected with FPRL1 (hereafter desig-
nated FPRL1/293 cells) were a gift of Drs. P.M. Murphy and
J.-L. Gao (National Institute of Allergy and Infectious Diseases,
NIH, Bethesda, MD) and were maintained in the presence of 2
mg/ml of geneticin in DME supplemented with 10% FBS.
 
Chemotaxis Assay.
 
Migration of neutrophils, monocytes, T
cells, and HEK293 or transfectant cells in response to chemotactic
factors was assessed using a 48-well microchemotaxis chamber
technique as previously described (17, 18). In brief, chemotactic
factors diluted in chemotaxis medium (CM; RPMI 1640 con-
taining 1% BSA) were placed in the wells of the lower compart-
ment of the chamber (Neuro Probe), and cells suspended in CM
were added to the upper compartment. The lower and upper
compartments were separated by a polycarbonate membrane (Os-
monics). After incubation at 37
 
8
 
C in humidified air with 5% CO
 
2
 
for a period of time (60 min for neutrophils, 90 min for mono-
cytes, 180 min for T cells, and 300 min for HEK293, ETFR, and
FPRL1/293 cells), the membranes were removed, scraped,
stained, and counted. The results are presented as number of cells
per high power field (no./HPF) or as chemotactic index (C.I.).
 
Ca
 
2
 
1
 
 Mobilization Assay.
 
Monocytes or FPRL1/293 cells
(10
 
7
 
 cells/ml in RPMI 1640 containing 10% FBS) were loaded
by incubating with 5 
 
m
 
M Fura-2 (Molecular Probes) at 24
 
8
 
C for
30 min in the dark. Subsequently, the loaded cells were washed
with and resuspended (10
 
6
 
 cells/ml) in saline buffer (138 mM
NaCl, 6 mM KCl, 1 mM CaCl
 
2
 
, 10 mM Hepes, 5 mM glucose,
and 1% BSA, pH 7.4). Each 2 ml of loaded cell suspension was
then transferred into a quartz cuvette, which was placed in a lu-
minescence spectrometer LS50 B (PerkinElmer). Ca
 
2
 
1
 
 mobiliza-
tion of the cells in response to chemotactic factors was measured
by recording the ratio of fluorescence emitted at 510 nm after se-
quential excitation at 340 and 380 nm.
 
Statistical Analysis.
 
Unless otherwise specified, all experiments
were performed at least three times, and the results show repre-
sentative experiments. The significance of the difference between
test and control groups was analyzed with a Student’s 
 
t
 
 test.
 
Results
 
We first tested whether LL-37 could induce the in vitro
migration of human peripheral blood monocytes, a critical
correlate of monocyte accumulation at sites of inflamma-
tion or injury. LL-37 induced monocyte migration in a
dose-dependent manner with an optimal concentration at
10
 
2
 
5
 
 M (Fig. 1 A). In addition, LL-37 also dose-depen-
dently induced Ca
 
2
 
1
 
 flux in monocytes (Fig. 1 B). A
checkerboard analysis revealed that, when equal concentra-
tions of LL-37 were present in both the lower and the up-
per wells, only a slight increase in cell migration was ob-
served (Table I). Thus, the migration of monocytes
induced by LL-37 was based predominantly on chemotaxis 
1071
 
Yang et al. Brief Definitive Report
 
rather than chemokinesis. Interestingly, after monocytes
were differentiated into immature dendritic cells, the im-
mature dendritic cells could not respond to LL-37 in terms
of either chemotaxis or Ca
 
2
 
1
 
 mobilization, presumably due
to the loss of functional expression of the receptor for LL-
37 (data not shown).
To characterize the nature of the receptor for LL-37, we
examined the effect of pertussis toxin (PTX), a reagent
known to selectively block Gi protein–coupled signaling,
 
on LL-37–induced monocyte chemotaxis. Treatment of
monocytes with PTX (200 ng/ml) at 37
 
8
 
C for 30 min al-
most completely inhibited subsequent cell migration in re-
sponse to LL-37, indicating that a Gi protein–coupled re-
ceptor might be involved in LL-37–induced monocyte
activation (Fig. 2 A).
The only previously known effect of LL-37 on mamma-
lian cells is its capacity to damage them at concentrations
above 5
 
 3 
 
10
 
2
 
5
 
 M. This cytocidal effect of LL-37 can be
blocked completely by the presence of human serum and
partially by porcine serum (10). To investigate the relation-
ship of the chemotactic effect of LL-37 to its cytocidal
effect, the influence of 10% human AB serum on LL-37–
induced chemotaxis was studied. LL-37–induced chemo-
taxis of monocytes was not significantly inhibited by the
presence of 10% human AB serum (Fig. 2 B), suggesting
that the chemotactic effect of LL-37 was independent of its
cytocidal effect.
Next, we proceeded to identify the receptor LL-37 uti-
lizes to mediate its chemotactic effect on monocytes. LL-37
must use a chemotactic receptor expressed by monocytes,
but not by monocyte-derived immature dendritic cells.
Of the 22 human chemotactic receptors (including 17
chemokine receptors and 5 classical chemoattractant recep-
Figure 1. Induction by LL-37 of migration of (A) and Ca21 flux in (B)
human monocytes. (A) The migration of monocytes (106 cells/ml) was
assessed by chemotaxis assay using 5-mm uncoated membranes. Sponta-
neous cell migration (without LL-37) was z30–50 cells per HPF. The
average C.I. (mean 6 SD) of triplicate wells is shown. *P , 0.05 when
compared with chemotaxis medium alone (open bar). (B) Arrow indi-
cates the time point at which LL-37 was applied to the cells.
 
Table I.
 
Checkerboard Analysis of LL-37–induced
Monocyte Migration
 
LL-37 in lower wells
(
 
m
 
M)
LL-37 in upper wells (
 
m
 
M)
01 1 0
0
 
40
 
 
 
6 
 
5
 
45 
 
6 
 
6 44 
 
6 
 
7
1 135 
 
6 
 
15
 
‡
 
50 
 
6 
 
8 40 
 
6 
 
6
10 495 
 
6 
 
29
 
‡
 
265 
 
6 
 
5
 
‡
 
95 
 
6 
 
2
 
*
 
Human monocytes were used at 10
 
6
 
 per ml. LL-37 peptide at the
specified concentrations was added to the lower wells of the chemotaxis
chamber, and monocytes in the absence or presence of the specified
concentration of LL-37 peptide were added to the upper wells of the
chemotaxis chamber. The average (mean 
 
6
 
 SD) of migrated monocytes
of triplicate wells is shown as no./HPF. 
 
*
 
P
 
 
 
,
 
 0.05 and 
 
‡
 
P
 
 
 
,
 
 0.01 as
compared with spontaneous monocyte migration (in bold type).
Figure 2. Effect of PTX (A) and serum (B) on LL-37–induced
chemotaxis of monocytes. (A) Monocytes were incubated with (closed
bar) or without (hatched bar) PTX at a final concentration of 200 ng/ml
for 30 min at 378C before performing chemotaxis assay. To show that
the spontaneous cell migration (C.M.) was not affected by PTX pretreat-
ment, the results are presented as no./HPF. (B) Chemotaxis assay was
performed in the absence (hatched bar) or presence (closed bar) of 10%
human AB serum, which can completely block the antimicrobial activity
of LL-37 at 1025 M. 
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tors) identified so far (19, 20), 9 of them, namely FPR,
FPRL1, platelet activating factor receptor (PAFR), C5aR,
CXCR4, CCR1, CCR2, CCR5, and CCR8, have been
demonstrated to be expressed by freshly isolated peripheral
blood monocytes at mRNA, protein, and functional levels
(19–21). 7 out of the 9 (FPR, PAFR, C5aR, CXCR4,
CCR1, CCR5, and CCR8) have also been shown to be
functionally expressed by monocyte-derived immature
dendritic cells (21, 22). Examination of HEK293 cells sta-
bly transfected to express CCR2 indicated that CCR2 was
not a receptor for LL-37 (data not shown). Fortuitously,
we recently determined that FPRL1 was downregulated in
the process of differentiation of monocytes into immature
dendritic cells (Yang, D., Q. Chen, J.M. Wang, and J.J.
Oppenheim, unpublished observation). We therefore in-
vestigated whether FPRL1 serves as a receptor for LL-37.
As shown by Fig. 3 A, FPRL1/293 cells, HEK293 cells
transfected to stably express FPRL1, migrated in response
to LL-37 in a dose-dependent manner, whereas the paren-
tal HEK293 cells did not respond, suggesting that FPRL1 is
a receptor for LL-37. The specificity of LL-37 interaction
with FPRL1 is further supported by the fact that cells ex-
pressing FPR (ETFR cells), which share the highest ho-
mology with FPRL1, also did not respond to LL-37 (Fig. 3
A). As expected, LL-37 also induced Ca
 
2
 
1
 
 flux in a dose-
dependent manner in FPRL1/293 cells (Fig. 3 B) but not
in ETFR cells (data not shown).
To ascertain that LL-37 also utilizes FPRL1 as a receptor
to mediate its effect on monocytes, we examined whether
LL-37–induced Ca
 
2
 
1
 
 flux in monocytes could be cross-
desensitized by Su peptide, an FPRL1-specific agonist. As
shown in Fig. 3 C, both Su peptide and LL-37 at 5 
 
3 
 
10
 
2
 
6
 
M induced Ca
 
2
 
1
 
 flux to a similar extent in freshly isolated
human peripheral blood monocytes (a and c, respectively).
Furthermore, the Ca
 
2
 
1
 
 flux induced by Su peptide at 5 
 
3
 
10
 
2
 
6
 
 M was almost completely desensitized by LL-37 at
10
 
2
 
5
 
 M (Fig. 3 C, b) and vice versa (Fig. 3 C, d). As cross-
desensitization of Ca
 
2
 
1
 
 flux is often due to two agonists act-
ing on the same receptor, we conclude that LL-37 utilizes
FPRL1 as a functional receptor. We further investigated
whether LL-37 could chemoattract freshly isolated human
peripheral blood neutrophils and T lymphocytes that are
known to express functional FPRL1 (17, 19). As expected,
LL-37 induced dose-dependent migration of highly purified
human neutrophils (Fig. 4 A) and CD4 T cells (Fig. 4 B).
Figure 3. LL-37 uses FPRL1 as its re-
ceptor. (A) Selective induction of FPRL1/
293 cell chemotaxis by LL-37. The migra-
tion of parental HEK293 (open bars),
FPRL1/293 (dotted bars), or ETFR
(closed bars) cells was assessed by chemo-
taxis assay with the use of collagen-coated
10-mm membranes. Cells were used at a
concentration of 106 cells/ml. The average
C.I. (mean 6 SD) of triplicate wells is
shown. Spontaneous cell migration (with-
out LL-37) was z10–20 cells per HPF.
*P , 0.05 when compared with chemo-
taxis medium alone. (B) LL-37–induced
Ca21 flux in FPRL1/293 cells. Arrow indi-
cates the time point at which LL-37 was
applied to the cells. (C) Cross-desensitiza-
tion of LL-37–induced Ca21 flux in mono-
cytes by FPRL1-specific agonistic ligand.
Arrows indicate the time points at which
LL-37 and Su peptides were applied to the
cells.
Figure 4. Chemotaxis of human neutrophils (A) and CD4 T lympho-
cytes (B) in response to LL-37. The cell migration was assessed by
chemotaxis assay with the use of uncoated (A) or fibronectin-coated (B)
5-mm membranes. The results are presented as the average C.I. (mean 6
SD) of triplicate wells. *P , 0.05 when compared with spontaneous cell
migration (chemotactic medium alone). Neutrophils and CD4 T cells
were used at a concentration of 106 cells/ml and 5 3 106 cells/ml, respec-
tively. Spontaneous neutrophil and T cell migration (without LL-37) was
z30–50 and z30–40 cells per HPF, respectively.1073 Yang et al. Brief Definitive Report
Discussion
In this study, we have demonstrated that LL-37 is
chemotactic for freshly isolated human peripheral blood
neutrophils, monocytes, and T cells and determined that
LL-37 utilizes FPRL1 as a receptor to mediate its chemo-
tactic and Ca21-mobilizing effects. So far, LL-37/hCAP18
has been considered to contribute to human innate defense
against microbial infection, based primarily on its selective
expression by neutrophils and epithelial cells facing the ex-
ternal environment, its in vitro antimicrobial activity, and
its capacity to bind and neutralize the biological effect of
bacterial endotoxin (1, 5). As leukocytes participate in both
innate and adaptive immunity, the fact that LL-37 can
chemoattract human leukocytes may provide one addi-
tional mechanism by which LL-37 contributes to host de-
fense against microbial invasion, by participating in the
recruitment of leukocytes to sites of infection. This mecha-
nism is potentially important in vivo, because the chemo-
tactic activity of LL-37, unlike its antimicrobial action (10),
is not significantly inhibited by the presence of 10% human
AB serum (Fig. 2 B).
The optimal concentration for LL-37 to chemoattract
human leukocytes was 1025 M (Fig. 1 A and Fig. 4). Most
chemotactic responses are usually based on “high-affinity
ligand–receptor interaction” (19, 20). It is likely that LL-
37–FPRL1 interaction represents a low-affinity ligand–
receptor interaction. Previously identified low-affinity
ligand–receptor interactions include multiple CXC chemo-
kines (growth-regulated oncogene, neutrophil-activating
peptide 2, and epithelial cell–derived neutrophil-activat-
ing peptide 78) for CXCR1 (23) and macrophage inflam-
matory protein 1b and monocyte chemoattractant protein
1 for CCR1 (24). Low-affinity ligand–receptor interactions
also contribute to the recruitment of leukocytes to the fo-
cus of inflammation (25). Multiple leukocyte chemotactic
factors, including LL-37, are likely to be generated at sites
of microbial invasion and presumably form a complex of
concentration gradients. As leukocytes traffic from the
lower to the higher levels of the chemotactic gradients,
their high-affinity chemotactic receptors are likely to be-
come deactivated through desensitization (25). Subsequent
low-affinity ligand–receptor interactions, such as LL-37–
FPRL1 interaction, can thus direct leukocytes closer to in-
flammatory foci. LL-37 expression can increase at both
mRNA and protein levels by .10–50-fold in response to
inflammatory stimuli (7, 9). The concentration of LL-37 in
the fluid from xenografts prepared with normal human air-
way epithelia is 2 mg/ml, equivalent to 4 3 1027 M (26).
Assuming that airway inflammation could also induce a 50-
fold increase in LL-37 expression, the LL-37 at the site of
airway inflammation would reach 2 3 1025 M. Thus, LL-
37 can potentially reach its optimal chemotactic concentra-
tion (1025 M) at local inflammatory sites.
In addition to LL-37, other known ligands for FPRL1
include bacterial formyl peptides (19), an ectodomain
of HIV gp41 termed T21 (17), a hexapeptide (Trp-Lys-
Tyr-Met-Val-d-Met-NH2) termed W peptide (27), serum
amyloid A (28), and even lipoxin A4, a lipid derivative of
arachidonate metabolism (29). Of these, serum amyloid A,
lipoxin A4, and LL-37 are endogenously generated and
increase dramatically during inflammation (7, 9, 28, 29).
Activation of the chemotactic receptor FPRL1 by these
endogenous ligands, including LL-37, results in a G pro-
tein–mediated signaling cascade leading to not only chemo-
taxis of leukocytes but also increased adhesion, enhanced
phagocytosis, release of oxygen intermediates, and aug-
mented bacterial killing (19, 20), thereby promoting anti-
microbial immunity. As LL-37 can also bind and neutralize
bacterial LPS (2), it may, on the other hand, limit the
adverse effects of inflammation by downregulating LPS-
induced inflammatory responses.
Defensins and cathelicidins represent two major types of
endogenous antimicrobial antibiotic peptides in higher
mammals, and their contribution to innate host defense
against microbial invasion is well established (1, 5). Based
on the chemotactic activities of a- and b-defensins (11, 12,
14) and the capacity of a-defensins to promote antigen-
specific immune responses (13), we proposed that defensins
also contribute to adaptive antimicrobial immunity by
alarming the adaptive immune system (12, 14). The results
showing that LL-37, the mature form of human cathelici-
din, is also chemotactic for human leukocytes predicts that
cathelicidins will also have the capacity to augment innate
and adaptive host defenses. Thus, mobilization and amplifi-
cation of immune responses may be a common feature for
endogenous antimicrobial peptides in higher vertebrates.
The identification of FPRL1 as the receptor that LL-37
utilizes to interact with human leukocytes should facilitate
more detailed investigation of the mechanism of cathelici-
dins’ roles in adaptive immunity.
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